Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10620819 | 0.79 | DYRK1A (0.35) | DYRK1A | |
| SCHEMBL3851653 | 0.78 | KDM4E (0.34) | — | |
| Hydrochloric Acid SCHEMBL8523808 | 0.78 | DYRK1A (0.34) | DYRK1A | |
| SCHEMBL9048951 | 0.78 | DYRK1A (0.34) | NOS1DYRK1ATGM2CES1 | |
| Benzodiazepine SCHEMBL7160172 | 0.72 | GAA (0.44) | — | |
| Benzodiazepine SCHEMBL8137 | 0.72 | GAA (0.44) | — | |
| Benzodiazepine SCHEMBL936208 | 0.71 | GAA (0.43) | — | |
| Benzodiazepine SCHEMBL11484022 | 0.71 | GAA (0.43) | — | |
| Benzodiazepine SCHEMBL6618830 | 0.71 | GAA (0.43) | — | |
| Benzodiazepine SCHEMBL31734455 | 0.71 | GAA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528127-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7485635-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-02-03 | — | — | US | disclosed |
| US-7473689-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-01-06 | — | — | US | disclosed |
| US-7435730-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2008-10-14 | — | — | US | disclosed |
| US-20070135420-A1 | e.g. Methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-pyrro[1,2-a][1,4]benzodiazepin-4-yl]propanoate; GABAA (gamma aminobutiric acid) receptor antagonist; sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant; anesthesia | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135419-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135421-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070093475-A1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
| US-7160880-B1 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| EP-1183243-B1 | SHORT-ACTING BENZODIAZEPINES | CENES LTD (GB) | 2006-02-08 | — | — | EP | disclosed |
| EP-1183243-A1 | SHORT-ACTING BENZODIAZEPINES | GLAXO GROUP LIMITED (GB) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069836-A1 | SHORT-ACTING BENZODIAZEPINES | GLAXO GROUP LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093475-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | NOS1 2759/4885METAP2 4476/4885CSNK2A1 730/4885 |
| US-20070135420-A1 | e.g. Methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-pyrro[1,2-a][1,4]benzodiazepin-4-yl]propanoate; GABAA (gamma aminobutiric acid) receptor antagonist; sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant; anesthesia | GABRA1, GABRA2, GABRA6 | NOS1 2933/4885METAP2 655/4885CSNK2A1 2372/4885 |
| US-20070135419-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | NOS1 2759/4885METAP2 4476/4885CSNK2A1 730/4885 |
| US-20070135421-A1 | Short-acting benzodiazepines | GABRA5, GABRA1, GABRA6 | NOS1 2759/4885METAP2 4476/4885CSNK2A1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.